Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.

Tytuł:
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Autorzy:
Aggarwal A; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Akerman A; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Milogiannakis V; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Silva MR; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Walker G; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Stella AO; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Kindinger A; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Angelovich T; School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia.
Waring E; School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia.
Amatayakul-Chantler S; Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring, Australia.
Roth N; Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland.
Manni S; Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland.
Hauser T; Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland.
Barnes T; Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland.
Condylios A; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Yeang M; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Wong M; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Jean T; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Foster CSP; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Christ D; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Hoppe AC; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Munier ML; The Kirby Institute, University of New South Wales, New South Wales, Australia.
Darley D; St Vincent's Hospital, Sydney, New South Wales, Australia.
Churchill M; School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia.
Stark DJ; Molecular Diagnostic Medicine Laboratory, Sydpath, St Vincent's Hospital, Sydney, New South Wales, Australia.
Matthews G; The Kirby Institute, University of New South Wales, New South Wales, Australia; St Vincent's Hospital, Sydney, New South Wales, Australia.
Rawlinson WD; Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia.
Kelleher AD; The Kirby Institute, University of New South Wales, New South Wales, Australia; St Vincent's Hospital, Sydney, New South Wales, Australia.
Turville SG; The Kirby Institute, University of New South Wales, New South Wales, Australia. Electronic address: .
Źródło:
EBioMedicine [EBioMedicine] 2022 Oct; Vol. 84, pp. 104270. Date of Electronic Publication: 2022 Sep 18.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
MeSH Terms:
COVID-19*/therapy
SARS-CoV-2*/genetics
Angiotensin-Converting Enzyme 2/genetics ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral/metabolism ; Antiviral Agents ; Australia ; BNT162 Vaccine ; Benzamidines ; Guanidines ; Humans ; Immunization, Passive ; Immunoglobulin G ; Immunotherapy ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism ; Tropism ; COVID-19 Serotherapy
References:
Nature. 2022 Feb;602(7897):487-495. (PMID: 34942634)
Cell. 2022 Feb 3;185(3):467-484.e15. (PMID: 35081335)
Nature. 2022 Mar;603(7902):706-714. (PMID: 35104837)
Nat Med. 2022 Sep;28(9):1785-1790. (PMID: 35760080)
Emerg Microbes Infect. 2022 Dec;11(1):277-283. (PMID: 34951565)
Lancet. 2021 Apr 10;397(10282):1347-1348. (PMID: 33770519)
Nat Commun. 2023 Mar 23;14(1):1620. (PMID: 36959194)
Cell Rep. 2022 Jun 28;39(13):111009. (PMID: 35732171)
Biologicals. 2008 Jul;36(4):239-47. (PMID: 18337119)
Nature. 2021 Nov;599(7883):114-119. (PMID: 34488225)
PLoS Med. 2021 Jul 6;18(7):e1003656. (PMID: 34228725)
Cell. 2022 Jul 7;185(14):2422-2433.e13. (PMID: 35772405)
Lancet Infect Dis. 2022 Aug;22(8):1117-1118. (PMID: 35777385)
Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645)
Mol Ther Methods Clin Dev. 2019 Dec 24;17:209-219. (PMID: 31970199)
Sci Rep. 2022 Jul 23;12(1):12609. (PMID: 35871089)
EMBO J. 2021 Dec 15;40(24):e108944. (PMID: 34601723)
Science. 2022 Aug 19;377(6608):890-894. (PMID: 35857529)
Nat Commun. 2021 Jun 8;12(1):3431. (PMID: 34103499)
J Infect Dis. 2021 Nov 22;224(10):1707-1711. (PMID: 34543421)
Nature. 2022 Aug;608(7923):593-602. (PMID: 35714668)
Signal Transduct Target Ther. 2022 Mar 9;7(1):76. (PMID: 35264568)
Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6. (PMID: 35921836)
Nature. 2022 Mar;603(7902):700-705. (PMID: 35104835)
Nature. 2022 Aug;608(7923):603-608. (PMID: 35790190)
Lancet Infect Dis. 2023 Feb;23(2):167-176. (PMID: 36270311)
N Engl J Med. 2022 Aug 4;387(5):468-470. (PMID: 35857646)
Nature. 2022 Mar;603(7902):687-692. (PMID: 35062015)
Nature. 2022 Jan;601(7892):177. (PMID: 34987210)
Nat Commun. 2020 Dec 9;11(1):6272. (PMID: 33298935)
Signal Transduct Target Ther. 2022 May 7;7(1):151. (PMID: 35525870)
N Engl J Med. 2022 Jul 7;387(1):86-88. (PMID: 35731894)
Nature. 2022 Mar;603(7902):715-720. (PMID: 35104836)
Science. 2021 Dec 24;374(6575):1626-1632. (PMID: 34735219)
World J Virol. 2016 May 12;5(2):85-6. (PMID: 27175354)
Nat Microbiol. 2022 Jun;7(6):896-908. (PMID: 35637329)
Nature. 2022 Mar;603(7902):693-699. (PMID: 35062016)
Contributed Indexing:
Keywords: ACE2; BA.2; BA.5; Neutralising antibodies; Omicron BA.1; SARS-CoV-2; TMPRSS2
Substance Nomenclature:
0 (Antibodies, Monoclonal, Humanized)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (Antiviral Agents)
0 (Benzamidines)
0 (Guanidines)
0 (Immunoglobulin G)
0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
1MTK0BPN8V (sotrovimab)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
N38TVC63NU (BNT162 Vaccine)
Y25LQ0H97D (nafamostat)
SCR Organism:
SARS-CoV-2 variants
Entry Date(s):
Date Created: 20220921 Date Completed: 20221018 Latest Revision: 20231105
Update Code:
20240105
PubMed Central ID:
PMC9482529
DOI:
10.1016/j.ebiom.2022.104270
PMID:
36130476
Czasopismo naukowe
Background: Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. The introduction of global vaccine programs has contributed to lower COVID-19 hospitalisation and mortality rates, particularly in developed countries. In late 2021, Omicron BA.1 emerged, with substantially altered genetic differences and clinical effects from other variants of concern. Shortly after dominating global spread in early 2022, BA.1 was supplanted by the genetically distinct Omicron lineage BA.2. A sub-lineage of BA.2, designated BA.5, presently has an outgrowth advantage over BA.2 and other BA.2 sub-lineages. Here we study the neutralisation of Omicron BA.1, BA.2 and BA.5 and pre-Omicron variants using a range of vaccine and convalescent sera and therapeutic monoclonal antibodies using a live virus neutralisation assay. Using primary nasopharyngeal swabs, we also tested the relative fitness of BA.5 compared to pre-Omicron and Omicron viral lineages in their ability to use the ACE2-TMPRSS2 pathway.
Methods: Using low passage clinical isolates of Clade A.2.2, Beta, Delta, BA.1, BA.2 and BA.5, we determined humoral neutralisation in vitro in vaccinated and convalescent cohorts, using concentrated human IgG pooled from thousands of plasma donors, and licensed monoclonal antibody therapies. We then determined infectivity to particle ratios in primary nasopharyngeal samples and expanded low passage isolates in a genetically engineered ACE2/TMPRSS2 cell line in the presence and absence of the TMPRSS2 inhibitor Nafamostat.
Findings: Peak responses to 3 doses of BNT162b2 vaccine were associated with a 9-fold reduction in neutralisation for Omicron lineages BA.1, BA.2 and BA.5. Concentrated pooled human IgG from convalescent and vaccinated donors and BNT162b2 vaccination with BA.1 breakthrough infections were associated with greater breadth of neutralisation, although the potency was still reduced 7-fold across all Omicron lineages. Testing of clinical grade antibodies revealed a 14.3-fold reduction using Evusheld and 16.8-fold reduction using Sotrovimab for the BA.5. Whilst the infectivity of BA.1 and BA.2 was attenuated in ACE2/TMPRSS2 entry, BA.5 was observed to be equivalent to that of an early 2020 circulating clade and had greater sensitivity to the TMPRSS2 inhibitor Nafamostat.
Interpretation: Observations support all Omicron variants to significantly escape neutralising antibodies across a range of vaccination and/or convalescent responses. Potency of therapeutic monoclonal antibodies is also reduced and differs across Omicron lineages. The key difference of BA.5 from other Omicron sub-variants is the reversion in tropism back to using the well-known ACE2-TMPRSS2 pathway, utilised efficiently by pre-Omicron lineages. Monitoring if these changes influence transmission and/or disease severity will be key for ongoing tracking and management of Omicron waves globally.
Funding: This work was primarily supported by Australian Medical Foundation research grants MRF2005760 (ST, GM & WDR), MRF2001684 (ADK and ST) and Medical Research Future Fund Antiviral Development Call grant (WDR), Medical Research Future Fund COVID-19 grant (MRFF2001684, ADK & SGT) and the New South Wales Health COVID-19 Research Grants Round 2 (SGT).
Competing Interests: Declaration of interests A.O.S contributed to this manuscript in his capacity as adjunct associate lecturer (from January 2022) at the University of New South Wales. Since January 2022, A.O.S is an employee of GlaxoSmithKline Australia (medical science liaison for COVID-19).
(Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies